Plasma Amyloid‐β Levels are Associated with Risk of Heart Failure: Framingham Heart Study

Abstract Background Amyloid‐β (Aβ) is a toxic polypeptide of 36‐43 amino acids formed during proteolysis. Initial studies suggest that protein misfolding, including abnormal aggregation of Aβ, is associated with cardiac dysfunction. Our objective is to investigate the association of circulating plasma amyloid‐β40 (Aβ40), amyloid‐β42 (Aβ42), and Aβ42/40 with the incidence of congestive heart failure (HF). Method We evaluated the association of plasma Aβ40, Aβ42, and Aβ42/40 with risk of HF in a community‐based sample from the prospective Framingham Heart Study. We included adult participants aged 45+ years, free from clinical HF at the time of blood draw (Offspring cohort, Exam 7, 1998‐2001). Plasma Aβ40 and Aβ42 were measured using the Fluorometric immunoassay platform. Aβ levels were natural log‐transformed to normalize the distribution. Using Cox regression models, each of these biomarkers were related to incident HF, adjusting for age and sex. Previous studies identified differences in the association of Aβ with HF by sex, so we tested for interaction by sex and reported stratified results when statistically significant (a=0.05). Result Among the 3,125 included participants (mean±SD age 62.1±8.9 years, 54% women), there were 146 (4.7%) incident HF events over 10 years of follow up. Higher plasma Aβ40 levels (per unit of the natural log of the protein level) were associated with an increased risk of HF (hazard ratio [HR] 95% confidence interval [CI], p): (2.04[1.03‐4.02], 0.040) but not with Aβ42 (1.48[0.74‐2.98], 0.273) and Aβ42/40 (0.73[0.37‐1.44], 0.365). We observed effect modification by sex in the association between each of the Aβ40 ( p = 0.032), Aβ42 ( p = 0.027) and risk of HF but not with Aβ42/40 ( p = 0.867). Stratified analyses revealed that Aβ40 and Aβ42 levels were associated with an increased risk of HF in men (HR 95%[CI], p): 4.50 [1.67‐12.11], 0.003) and (3.14 [1.19‐8.27], 0.021), respectively but not in women (0.96 [0.37, 2.53], 0.937) and (0.64 [0.24, 1.73], 0.381), respectively. Conclusion Elevated plasma levels of Aβ40 and Aβ42 were associated with higher risk of heart failure, in men only. These results provide further evidence that circulating proteins in the blood can provide prognostic information on diseases affecting the brain‐heart axis, possibly linked by protein misfolding or aggregation.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_106223
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma Amyloid‐β Levels are Associated with Risk of Heart Failure: Framingham Heart Study

Edwin R. van den Heuvel, Jose Rafael Romero, Dibya Himali, Vasileios‐Arsenios Lioutas et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Plasma Amyloid‐β Levels are Associated with Risk of Heart Failure: Framingham Heart Study

Edwin R. van den Heuvel, Jose Rafael Romero, Dibya Himali, Vasileios‐Arsenios Lioutas, Jeremy Tanner, Jayandra J. Himali, Alexa S Beiser, Hugo J. Aparicio, Matthew P. Pase, Sudha Seshadri, Emer McGrath
article en

Abstract

Abstract Background Amyloid‐β (Aβ) is a toxic polypeptide of 36‐43 amino acids formed during proteolysis. Initial studies suggest that protein misfolding, including abnormal aggregation of Aβ, is associated with cardiac dysfunction. Our objective is to investigate the association of circulating plasma amyloid‐β40 (Aβ40), amyloid‐β42 (Aβ42), and Aβ42/40 with the incidence of congestive heart failure (HF). Method We evaluated the association of plasma Aβ40, Aβ42, and Aβ42/40 with risk of HF in a community‐based sample from the prospective Framingham Heart Study. We included adult participants aged 45+ years, free from clinical HF at the time of blood draw (Offspring cohort, Exam 7, 1998‐2001). Plasma Aβ40 and Aβ42 were measured using the Fluorometric immunoassay platform. Aβ levels were natural log‐transformed to normalize the distribution. Using Cox regression models, each of these biomarkers were related to incident HF, adjusting for age and sex. Previous studies identified differences in the association of Aβ with HF by sex, so we tested for interaction by sex and reported stratified results when statistically significant (a=0.05). Result Among the 3,125 included participants (mean±SD age 62.1±8.9 years, 54% women), there were 146 (4.7%) incident HF events over 10 years of follow up. Higher plasma Aβ40 levels (per unit of the natural log of the protein level) were associated with an increased risk of HF (hazard ratio [HR] 95% confidence interval [CI], p): (2.04[1.03‐4.02], 0.040) but not with Aβ42 (1.48[0.74‐2.98], 0.273) and Aβ42/40 (0.73[0.37‐1.44], 0.365). We observed effect modification by sex in the association between each of the Aβ40 ( p = 0.032), Aβ42 ( p = 0.027) and risk of HF but not with Aβ42/40 ( p = 0.867). Stratified analyses revealed that Aβ40 and Aβ42 levels were associated with an increased risk of HF in men (HR 95%[CI], p): 4.50 [1.67‐12.11], 0.003) and (3.14 [1.19‐8.27], 0.021), respectively but not in women (0.96 [0.37, 2.53], 0.937) and (0.64 [0.24, 1.73], 0.381), respectively. Conclusion Elevated plasma levels of Aβ40 and Aβ42 were associated with higher risk of heart failure, in men only. These results provide further evidence that circulating proteins in the blood can provide prognostic information on diseases affecting the brain‐heart axis, possibly linked by protein misfolding or aggregation.

Alzheimer s & DementiaVol. 21(S2)
Boston University (US), Beth Israel Deaconess Medical Center (US), The University of Texas at San Antonio Health Science Center (US), Ollscoil na Gaillimhe – University of Galway (IE), Institute for Neurodegenerative Disorders (US), Framingham Heart Study (US), The University of Texas at San Antonio (US), Monash University (AU)
Good health and well-being
Openalex Percentile: Top 31%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.